-12.3 C
New York
Monday, February 9, 2026

This Key Gene-Editing Test Is Dragging Down All CRISPR Stocks

Intellia Therapeutics (NTLA) said early Friday it found a way to knock out the gene responsible for a rare and deadly swelling disorder — but NTLA …

This post was originally published on this site

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

149,544FansLike
396,312FollowersFollow
2,640SubscribersSubscribe

Latest Articles

0
Would love your thoughts, please comment.x
()
x